NCT06474039RecruitingPhase 3
The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
Source: ClinicalTrials.gov · Last updated 6 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 19 Jun 2024
- Start date
- 1 Oct 2024
- Primary completion date
- Jun 2026
- Lead sponsor
- Mahidol University
- Diseases
- COPD
- NCT number
- NCT06474039
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 50
- From 1 Oct 2024 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.
- Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids
- Being treated with triple therapy (ICS/LABA/LAMA)
Other illness
- Being in terminally ill conditions
Who the study is looking for
- Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.
- Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators
- Patients who are able to provide informed consent.
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Division of Respiratory Disease and TB, Siriraj Hospital Coordinator of this site? Confirm its status | Bangkoknoi | Thailand | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.